RAPT Therapeutics, Inc.
NNASDAQ:RAPTShare Statistics
As of September 30, 2025, RAPT Therapeutics, Inc. has 16.86M shares outstanding.
| Shares Outstanding | 16.86M |
Valuation Ratios
These figures are as of September 30, 2025.
| PB Ratio | -0.84 |
| P/TBV Ratio | 3.68 |
| P/FCF Ratio | -6.46 |
| P/OCF Ratio | -6.45 |
Financial Position
As of September 30, 2025, RAPT Therapeutics, Inc. maintains a current ratio of 12.04, meaning it holds 12.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.04 |
| Quick Ratio | 11.76 |
| Debt / Equity | 1.71 |
| Debt / EBITDA | -0.02 |
Financial Efficiency
These figures cover the twelve months ended September 30, 2025. Return on assets (ROA) is negative at -77.05, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -77.05 |
Dividends & Yields
These figures cover the twelve months ended September 30, 2025. Free cash flow yield is negative at -15.48: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.64, meaning RAPT Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -25.64 |
| FCF Yield | -15.48 |
Stock Splits
RAPT Therapeutics, Inc.'s most recent stock split took place on June 17, 2025 with a 8:1 split ratio.
| Last Split Date | 6/17/2025 |
| Split Ratio | 8:1 |
Scores
As of September 30, 2025, RAPT Therapeutics, Inc. has an Altman Z-Score of 17.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 17.56 |